Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout

BACKGROUND: Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout. The objective of this study was to evaluate the efficacy and safety of topiroxostat in hyperuricemic stage 3 chronic kidney disease pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosoya, Tatsuo, Ohno, Iwao, Nomura, Shinsuke, Hisatome, Ichiro, Uchida, Shunya, Fujimori, Shin, Yamamoto, Tetsuya, Hara, Shigeko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271138/
https://www.ncbi.nlm.nih.gov/pubmed/24448692
http://dx.doi.org/10.1007/s10157-014-0935-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271138/
https://www.ncbi.nlm.nih.gov/pubmed/24448692
http://dx.doi.org/10.1007/s10157-014-0935-8

Ejemplares similares